abderrazzak merzouki   zoominfocom abderrazzak merzouki sunshine biopharma inc profile  biography  bloomberg feedback abderrazzak merzouki chief operating officer sunshine biopharma inc career history chief operating officer sunshine biopharma inc present business advisor spencer pharmaceutical inc present senior scientist montreal ecole polytechnique present directorcell engineering a laboratories inc  professorimmunology institut armandfrappier  directorcell engineering hydrogen future corp unknown research scientistprofessor virologyimmunology former consultant introgen therapeutics inc former consultant gencell former consultant aventis pharma former consultant alert b  c corp former consultant id biomedical corp former consultant shire former consultant rhone poulencrorer former show more website wwwsunshinebiopharmacom corporate information address  royalmount avenue montreal qc hp r canada phone  fax  web url wwwsunshinebiopharmacom from the web personal information education institut armandfrappier phd  institut armandfrappier masters degree science memberships board memberships sunshine biopharma inc board member present sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data spencer pharmaceutical inc announces dr abderrazzak merzouki joins the scientific advisory board and business advisorhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoreyahoosearchsearchskip to navigationskip to main contentskip to related contentspencer pharmaceutical inc announces dr abderrazzak merzouki joins the scientific advisory board and business advisormarketwireoctober  reblogsharetweetshareboston mamarketwire    spencer pharmaceutical inc pinksheetsspph  news announced today the addition of dr abderrazzak merzouki to join its scientific advisory board as well as accepting a position as a business advisor with the companythe management of spencer pharmaceutical inc is delighted to announce the addition of dr merzouki to the scientific advisory board he brings a wealth of scientific research knowledge to the team dr merzouki is a research scientist and professor of virologyimmunologyhe is currently teaching and lecturing at the institute of biomedical engineering department of chemical engineering at ecole polytechnique de montreal since  as a senior scientist where he currently manages a suite of molecular and cell biology laboratoriesdr merzouki is a molecular biologist and an immunologist with a long experience in the gene therapy area where he has performed several preclinical and clinical analysis for pharmaceutical companies involving the use of adenoviral vectors for cancer introgen therapeutics inc usa gencell asiapacific japan and dna plasmid vectors for peripheral artery occlusive disease aventis pharma franceusa dr merzouki has an extensive expertise in the design of expressing vectors production and purification of recombinants proteins he developed technologies patents pending for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer diabetes hepatitis or multiple sclerosis stated dr max arella ceo and chairman of spencer pharmaceutical inc we are pleased that dr merzouki has accepted to serve spencer pharmaceutical as a scientific and business advisor his extensive network in scientific and businesses circles in the middle eastnorth africa regions will certainly be a major asset for our company in future negotiations in this part of the world concluded dr arellaabout spencer pharmaceutical incspencer pharmaceutical inc is a us based pharmaceutical research and development corporation which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndromeimportant informationabout forwardlooking statements in this press release may be forwardlooking statements within the meaning of the private securities litigation reform act of  words such as anticipate believe estimate expect intend and similar expressions as they relate to the company or its management identify forwardlooking statements these statements are based on current expectations estimates and projections about the companys business based in part on assumptions made by management these statements are not guarantees of future performance and involve risks uncertainties and assumptions that are difficult to predict therefore actual outcomes and results may and probably will differ materially from what is expressed or forecasted in such forwardlooking statements due to numerous factors including those described above in addition such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material product demand market and customer acceptance competition pricing and development difficulties as well as general industry and market conditions and growth rates and general economic conditions any forwardlooking statements speak only as of the date on which they are made and the company does not undertake any obligation to update any forwardlooking statement to reflect events or circumstances after the date of this release information on the companys website does not constitute a part of this releasereblogsharetweetsharepopular in the communityyearold runs to neighbor for help as her yearold sister is allegedly being raped senseless and awful reactionswomen everywhere should carry this tiny devicesiren songsponsoredmobile medical clinics deliver needed care in virginia reactionsclarifying the ‘goldwater rule’ for psychotherapists in the age of trump reactionsmacaulay culkin steps out to dinner with brenda song in rare appearance pics reactionsengineer finds pattern makes millions in stocksmoney morningsponsoredprotesters across the country oppose gops health care plan reactionssessions under siege as trump continues belittling public attacks reactionsluis fonsi on justin biebers spanish despacito hitting no  reactionsa pennycrypto miracle making some americans richagora financialsponsoredmother comes home to find child covered in blood and saying she was sexually abused reactionstinder couple whose  years of messages went viral meets for st time on gma reactionsmccain ‘i will not vote for this bill as it is today’ reactions home faux pas that embarrass the neighborswayfairsponsoreddrawing in the customers in mogadishu reactionsrazorthin victory on capitol hill for trumps health care reactionsus energy secretary duped into fake interview with russian comediansbob hope theyre proud of themselves how hard is it to prank a moronjoin the conversation   abderrazzak merzouki inventions patents and patent applications  justia patents search log in sign up find a lawyer ask a lawyer research the law law schools laws  regs newsletters legal marketing patents by inventor abderrazzak merzouki abderrazzak merzouki has filed for patents to protect the following inventions this listing includes patent applications that are pending as well as patents that have already been granted by the united states patent and trademark office uspto compositions and methods for efficacious and safe delivery of sirna using specific chitosanbased nanocomplexes publication number  abstract there is disclosed a composition and a method for the efficient delivery of a therapeutic rnaiinducing nucleic acid to cells both in vitro and in vivo through specific formulations of a non viral delivery system using chitosans particularly the composition contains a nucleic acid and a specific chitosan that has the following physicochemical properties a numberaverage molecular weight between  kda and  kda a degree of deacetylation between  and  and a chitosan amine to nucleic acid phosphate ratio below  type application filed december   publication date june   applicant polyvalor limited partnership inventors abderrazzak merzouki michael d buschmann compositions and methods for efficacious and safe delivery of sirna using specific chitosanbased nanocomplexes publication number  abstract there is disclosed a composition and a method for the efficient delivery of a therapeutic rnaiinducing nucleic acid to cells both in vitro and in vivo through specific formulations of a non viral delivery system using chitosans particularly the composition contains a nucleic acid and a specific chitosan that has the following physicochemical properties a numberaverage molecular weight between  kda and  kda a degree of deacetylation between  and  and a chitosan amine to nucleic acid phosphate ratio below  type application filed may   publication date march   inventors abderrazzak merzouki michael d buschmann gene therapy for diabetes with chitosandelivered plasmid encoding glucagonlike peptide  publication number  abstract chitosan delivers a plasmid encoding glucagonlike peptide  glp to cells in a patient for gene therapy of diabetes chitosan is optimized for plasmid transfection by modulating three of its physicochemical properties degree of deacetylation dda molecular weight mw and ratio of amines on chitosan to phosphates on dna np ratio chitosan  ddamwnp is more efficient than chitosans  and  in delivering a plasmid encoding luciferase or glp to cells in the zucker diabetic fatty zdf rat model of diabetes chitosandelivered pvax plasmid encoding glp lowers glucose levels increases insulin production and reduces weight gain type application filed may   publication date august   applicant corporation de lecole polytechnique de montreal inventors abderrazzak merzouki michael d buschmann ask a lawyer question add details  additional details  ask question find a lawyer lawyers  get listed now get a free directory profile listing justia legal resources find a lawyer bankruptcy lawyers business lawyers criminal lawyers employment lawyers estate planning lawyers family lawyers personal injury lawyers more individuals bankruptcy criminal divorce dui estate planning family law personal injury more business business formation business operations employment intellectual property international trade real estate tax law more law students law schools admissions financial aid course outlines law journals blogs employment more us federal law us constitution us code regulations supreme court circuit courts district courts dockets  filings more us state law state constitutions state codes state case law california florida new york texas more other databases legal blogs legal forms gao reports product recalls patents trademarks countries more legal marketing websites blogs content social media local marketing paid ads cpcppc lawyer directory more   justia company terms of service privacy policy help marketing solutions publications authored by abderrazzak merzouki  pubfactscom abderrazzak merzouki are you abderrazzak merzouki   register this author register this author institute of biomedical engineeringcanada toggle navigation publications publications publications reads of chitosans for delivery of nucleic acids authors michael d buschmann abderrazzak merzouki marc lavertu marc thibault myriam jean vincent darrasadv drug deliv rev  aug  epub  jul dept chemical engineering and inst biomedical engineering ecole polytechnique montreal qc canada electronic address august  download full paper immobilized carboxymethylated dextran coatings for enhanced elisa authors benoît liberelle abderrazzak merzouki gregory de crescenzoj immunol methods  mar  epub  dec department of chemical engineering biop research unit ecole polytechnique de montréal po box  station centreville montréal québec canada hc amarch  download full paper advaa a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells authors abderrazzak merzouki michael d buschmann myriam jean rebecca s young si liao susannah gal zuomei li steve n slilatyanticancer res  octdepartment of chemical engineering école polytechnique institute of biomedical engineering po box  station centreville montréal québec canada hc a october  download full paper low molecular weight chitosan nanoparticulate system at low np ratio for nontoxic polynucleotide delivery authors mohamad alameh diogo dejesus myriam jean vincent darras marc thibault marc lavertu michael d buschmann abderrazzak merzoukiint j nanomedicine   epub  mar institute of biomedical engineering department of chemical engineering école polytechnique montréal qc canadamarch  download full paper chitosanbased therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type  diabetes authors myriam jean mohamad alameh diogo de jesus marc thibault marc lavertu vincent darras monica nelea michael d buschmann abderrazzak merzoukieur j pharm sci  jan  epub  nov institute of biomedical engineering department of chemical engineering école polytechnique po box  station centreville montréal québec canadajanuary  download full paper excess polycation mediates efficient chitosanbased gene transfer by promoting lysosomal release of the polyplexes authors marc thibault mélina astolfi nicolas trankhanh marc lavertu vincent darras abderrazzak merzouki michael d buschmannbiomaterials  jul  epub  mar department of chemical engineering école polytechnique montreal québec canadajuly  download full paper new elisa approach based on coiledcoil interactions authors benoît liberelle laurence bartholin cyril boucher frédéric murschel mario jolicoeur yves durocher abderrazzak merzouki gregory de crescenzoj immunol methods  oct  epub  oct department of chemical engineering biop research unit institute of biomedical engineering groupe de recherche en sciences et technologies biomédicales ecole polytechnique de montréal po box  station centreville montréal qc canada hc aoctober  download full paper chitosanasebased method for rna isolation from cells transfected with chitosansirna nanocomplexes for realtime rtpcr in gene silencing authors mohamad alameh myriam jean diogo dejesus michael d buschmann abderrazzak merzoukiint j nanomedicine  aug  epub  aug institute of biomedical engineering department of chemical engineering école polytechnique station centreville montréal qc canadaaugust  download full paper identification and characterization of a putative baculoviral transcriptional factor ie from choristoneura fumiferana granulovirus authors kianoush khajeh rashidan nasha nassoury abderrazzak merzouki claude guertinj biochem mol biol  novinstitut national de la recherche scientifiqueinstitut armandfrappier québec canadanovember  download full paper molecular characterization of three new avian infectious bronchitis virus ibv strains isolated in quebec authors ridha smati amer silim claude guertin marc henrichon mehdi marandi max arella abderrazzak merzoukivirus genes  inrslnstitut anmandfrappier centre of microbiology and biotechnology laval quebec canadaseptember  download full paper of abderrazzak merzouki  researcher profile  symptomacom close login email password login forgot password abderrazzak merzouki research topics by  publications citations   • diseases x coronavirus infections x diabetes mellitus type  x breast neoplasms x small cell lung carcinoma register to see all go coauthor network coauthor  copublications coauthor  copublications michael d buschmann  myriam jean  vincent darras  marc lavertu  marc thibault  mohamad alameh  gregory de crescenzo  diogo dejesus  claude guertin  benoit liberelle  max arella  register to see all go publications top   referenced new elisa approach based on coiledcoil interactions  l bartholin c boucher g de crescenzo y durocher m jolicoeur b liberelle f murschel identification and characterization of a putative baculoviral transcriptional factor ie from choristoneura fumiferana granulovirus  c guertin n nassoury kk rashidan advaa a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells  md buschmann s gal m jean z li s liao sn slilaty rs young immobilized carboxymethylated dextran coatings for enhanced elisa  g de crescenzo b liberelle molecular characterization of three new avian infectious bronchitis virus ibv strains isolated in quebec  m arella c guertin m henrichon m marandi a silim r smati register to see all go institutes institute institute register to see all go no map available title and abstract from medline®pubmed® a database of the us national library of medicinedata mined from medline®pubmed® a database of the us national library of medicine last medline®pubmed® update st of december  symptoma examples subscribe login close please enter your email address to search again continue physician patient a labs expands management for the development of interferon projects employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       a labs expands management for the development of interferon projects tweet   am montreal quebecmarketwire  november    a laboratories inc a labs otcbb aflb today announced the appointment of dr abderrazzak merzouki to the position of director of cell engineering and biotherapeutics dr merzouki is molecular biologist and immunologist with extensive experience in the advancement of biological molecules such as interferons through their preclinical and clinical phases of analysis and development he has previously been a consultant in the development of products for introgen therapeutics inc gencell japan aventis pharma genomics one id biomedical shire and rhone poulenc rorer in his role at a labs dr merzouki will direct all aspects of interferon product development as well as strengthening and enhancement of the companys patent portfolio dr merzouki obtained his msc and phd in immunology from armandfrappier institute in quebec in  and received his postdoctoral training at the university of british columbia and bc center for excellence in hivaids research from  until  he was professor of immunology at the armandfrappier institute in  dr merzouki joined the institute of biomedical engineering at the ecole polytechnique de montreal as a senior scientist where he has directly been involved in the latest research and development of interferon based therapies dr merzouki has over  publications in the most respected journals in the field of cellular and molecular biology i am very pleased to welcome dr merzouki to our interferon development team his extensive knowledge of the latest developments in interferon therapies will provide a significant depth to our management and will put a labs at the forefront of interferon product development said dr richard azani president and ceo about a labs a labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in north america the company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization safe harbor statement except for historical information contained herein the matters set forth above may be forwardlooking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forwardlooking statements words such as anticipate believe estimate expect intend and similar expressions as they relate to a its management or its ability to develop interferon products or strengthen its intellectual property identify forwardlooking statements such forwardlooking statements are based on the current beliefs of management as well as assumptions made by and information currently available to management actual results could differ materially from those contemplated by the forwardlooking statements as a result of certain factors such as the level of business and consumer spending the amount of sales of as products the competitive environment within the industry the ability of a to continue to expand its operations the level of costs incurred in connection with as expansion efforts economic conditions in the industry and the financial strength of as customers and suppliers a does not undertake any obligation to update such forwardlooking statements investors are also directed to consider all other risks and uncertainties contactsa laboratories incinvestor relationsmiradorinfoalabscomwwwalabscom read at biospacecom related news a labs signs partnership agreement for the production of interferon products idenix pharmaceuticals inc idix says ceo resigns promotes cfo a labs engages mirador consulting for financial advisory and public relations representation agensys inc announces retirement of donald rice and appointment of sef kurstjens as ceo and president a labs granted us provisional patent number us  for the production of interferonbased products bioscrip bios profit lags withdraws outlook ceo to quit a labs completes validation of cro equipment aoxing pharmaceutical company inc axn cfo resigns a labs begins operating environmental assessment business dr ludo reynders appointed chief executive officer of premier research please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • a labs   • biotechpharma  personnel                 a laboratories inc expands management for the development of interferon projectshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoreyahoosearchsearchskip to navigationskip to main contentskip to related contenta laboratories inc expands management for the development of interferon projectsmarketwirenovember  reblogsharetweetsharemontreal quebecmarketwire    a laboratories inc a labs otcbbaflb  news today announced the appointment of dr abderrazzak merzouki to the position of director of cell engineering and biotherapeutics dr merzouki is molecular biologist and immunologist with extensive experience in the advancement of biological molecules such as interferons through their preclinical and clinical phases of analysis and development he has previously been a consultant in the development of products for introgen therapeutics inc gencell japan aventis pharma genomics one id biomedical shire and rhone poulenc rorer in his role at a labs dr merzouki will direct all aspects of interferon product development as well as strengthening and enhancement of the companys patent portfoliodr merzouki obtained his msc and phd in immunology from armandfrappier institute in quebec in  and received his postdoctoral training at the university of british columbia and bc center for excellence in hivaids research from  until  he was professor of immunology at the armandfrappier institute in  dr merzouki joined the institute of biomedical engineering at the ecole polytechnique de montreal as a senior scientist where he has directly been involved in the latest research and development of interferon based therapies dr merzouki has over  publications in the most respected journals in the field of cellular and molecular biologyi am very pleased to welcome dr merzouki to our interferon development team his extensive knowledge of the latest developments in interferon therapies will provide a significant depth to our management and will put a labs at the forefront of interferon product development said dr richard azani president and ceoabout a labsa labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in north america the company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercializationsafe harbor statementexcept for historical information contained herein the matters set forth above may be forwardlooking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forwardlooking statements words such as anticipate believe estimate expect intend and similar expressions as they relate to a its management or its ability to develop interferon products or strengthen its intellectual property identify forwardlooking statements such forwardlooking statements are based on the current beliefs of management as well as assumptions made by and information currently available to management actual results could differ materially from those contemplated by the forwardlooking statements as a result of certain factors such as the level of business and consumer spending the amount of sales of as products the competitive environment within the industry the ability of a to continue to expand its operations the level of costs incurred in connection with as expansion efforts economic conditions in the industry and the financial strength of as customers and suppliers a does not undertake any obligation to update such forwardlooking statements investors are also directed to consider all other risks and uncertaintiesreblogsharetweetsharepopular in the communityyearold runs to neighbor for help as her yearold sister is allegedly being raped senseless and awful reactionswomen everywhere should carry this tiny devicesiren songsponsoredmobile medical clinics deliver needed care in virginia reactionsclarifying the ‘goldwater rule’ for psychotherapists in the age of trump reactionsmacaulay culkin steps out to dinner with brenda song in rare appearance pics reactionsengineer finds pattern makes millions in stocksmoney morningsponsoredprotesters across the country oppose gops health care plan reactionssessions under siege as trump continues belittling public attacks reactionsluis fonsi on justin biebers spanish despacito hitting no  reactionsthe f is no match for this planethe brofessionalsponsoredmother comes home to find child covered in blood and saying she was sexually abused reactionstinder couple whose  years of messages went viral meets for st time on gma reactionsmccain ‘i will not vote for this bill as it is today’ reactionsa pennycrypto miracle making some americans richagora financialsponsoreddrawing in the customers in mogadishu reactionsrazorthin victory on capitol hill for trumps health care reactionsus energy secretary duped into fake interview with russian comediansbob hope theyre proud of themselves how hard is it to prank a moronjoin the conversation   insider trading  merzouki abderrazzak  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  merzouki abderrazzak select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm nana sunshine biopharma inc sbfm merzouki abderrazzakchief operating officerdirector   direct view option award  am nana sunshine biopharma inc sbfm merzouki abderrazzakchief operating officerdirector   direct view   secformcom all rights reserved archives        wed  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement